

# Neurodegeneration

## Mitoquinone

Mitochondria-targeted antioxidant. Prevents early neuropathology in a mouse model of Alzheimer's disease.<sup>1</sup>

**Product No: 10-1363** 5 mg/ 25 mg/

## Preladenant

Potent and selective adenosine A2A antagonist. Efficacious in rodent and primate models of Parkinson's disease.<sup>2,3</sup>

**Product No: 10-4102** 5 mg/ 25 mg/

## PLX5622

Highly selective CSF1R inhibitor. Neuroprotectant and microglia-depletion agent.<sup>4</sup>

**Product No: 10-4726** 5 mg/ 25 mg/

## TTK21

CBP/p300 histone acetyltransferase activator. Promotes axon growth, sprouting, and synaptic plasticity.<sup>5</sup>

**Product No: 10-5669** 5 mg/ 25 mg/

## Urolithin A

Mitophagy inducer. Improves cognitive deficits in mouse model of Alzheimer's disease.<sup>6</sup>

**Product No: 10-3722** 50 mg/ 1 g/

## MF-438

Stearoyl-CoA desaturase 1 (SCD1) inhibitor. Fully restores growth in a cellular model of  $\alpha$ -synuclein neurotoxicity.<sup>7</sup>

**Product No: 10-4558** 5 mg/ 25 mg/

## N-Eicosanoyl serotonin

Induces hypophosphorylation of  $\alpha$ -synuclein. It preserved neuronal integrity and function, diminished neuroinflammation and improved behavioral performance. It prevents A $\beta$ -induced impairments in mouse models of Alzheimer's disease.<sup>8,9</sup>

**Product No: 10-3631** 10 mg/ 50 mg/

## HET0016

CYP4A and 4F inhibitor. Displays neuroprotective effects in a rat model of traumatic brain injury via inhibition of neuronal pyroptosis.<sup>10</sup>

**Product No: 10-5246** 5 mg/ 25 mg/

## P7C3-A20

A neuroprotective and proneurogenic agent acting *via* NAMPT stimulation.<sup>11</sup>

**Product No: 10-3414** 5 mg/ 25 mg/

## Sildenafil citrate

PDE5 inhibitor associated with a decreased risk of Alzheimer's disease. Increases neurite outgrowth and decreases phosphor-tau expression in neuronal models.<sup>12</sup>

**Product No: 10-1221** 10 mg/ 50 mg/

## PNU-282987


A7nAChR agonist that promotes clearance of  $\alpha$ -synuclein and protects against apoptosis induced by  $\alpha$ -synuclein fibrils.<sup>13</sup>

**Product No: 10-4496** 10 mg/ 50 mg/


## Deprenyl

Potent monoamine oxidase B (MAO-B) inhibitor used in the treatment of Parkinson's disease.<sup>14</sup>


**Product No: 10-1143** 100 mg/ 1 g/



Preladenant



TTK21



HET0016

## REFERENCES

1. McManus et al. (2011) *J. Neurosci.* **31** 15703
2. Hodgson et al. (2010) *Exp. Neurol.* **225** 384
3. Pinna et al. (2016) *Mov. Disord.* **31** 501
4. Dagher et al. (2015) *J. Neuroinflammation* **12** 139
5. Muller et al. (2022) *PLoS Biol.* **20** e3001310
6. Jayatunga et al. (2021) *Nutrients* **13** 3744
7. Terry-Kantor et al. (2020) *Int. J. Mol. Sci.* **21** 5193
8. Asam et al. (2017) *PLoS One* **12** e0189413
9. Basurto-Islas et al. (2014) *Neurobiol. Aging* **35** 2701
10. Chen et al. (2023) *Neuropharmacology* **239** 109687
11. LoCoco et al. (2017) *ELife* **6** e29626
12. Fang et al. (2021) *Nat. Aging* **1** 1175
13. McLean et al. (2016) *Behav. Brain Res.* **302** 73
14. Gerlach et al. (1992) *Eur. J. Pharmacol.* **226** 97